| Trial ID: | L0782 |
| Source ID: | NCT03738358
|
| Associated Drug: |
Trehalose
|
| Title: |
A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Trehalose in Patients With Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Fatty Liver
|
| Interventions: |
Dietary Supplement: Trehalose;Other: Placebo
|
| Outcome Measures: |
Change in liver fat content scanned by CTChange in ALT and AST;Change in homeostatic model assessment-insulin resistance (HOMA-IR);Change in total cholesterol, LDL, HDL, triglyceride (TG) and free fatty acid;Change in BMI;Change in visceral fat and subcutaneous fat levels;Adverse event (AE)
|
| Sponsor/Collaborators: |
Samsung Medical Center
|
| Gender: |
All
|
| Age: |
19 Years79 Years
|
| Phases: |
Not applicable
|
| Enrollment: |
39
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
|
| Start Date: |
08/11/2018
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 December 2020
|
| Locations: |
--
|
| URL: |
https://clinicaltrials.gov/show/NCT03738358
|
